• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过CHO细胞展示实现单链抗体稳定性和亲和力的同时成熟

Simultaneous Maturation of Single Chain Antibody Stability and Affinity by CHO Cell Display.

作者信息

Luo Ruiqi, Qu Baole, An Lili, Zhao Yun, Cao Yang, Ren Peng, Hang Haiying

机构信息

Key Laboratory for Protein and Peptide Pharmaceuticals, National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China.

University of Chinese Academy of Sciences, Beijing 100049, China.

出版信息

Bioengineering (Basel). 2022 Aug 2;9(8):360. doi: 10.3390/bioengineering9080360.

DOI:10.3390/bioengineering9080360
PMID:36004885
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9404881/
Abstract

Antibody stability and affinity are two important features of its applications in therapy and diagnosis. Antibody display technologies such as yeast and bacterial displays have been successfully used for improving both affinity and stability. Although mammalian cell display has also been utilized for maturing antibody affinity, it has not been applied for improving antibody stability. Previously, we developed a Chinese hamster ovary (CHO) cell display platform in which activation-induced cytidine deaminase (AID) was used to induce antibody mutation, and antibody affinity was successfully matured using the platform. In the current study, we developed thermo-resistant (TR) CHO cells for the purpose of maturing both antibody stability and affinity. We cultured TR CHO cells displaying an antibody mutant library and labeled them at temperatures above 41 °C, enriching cells that displayed antibody mutants with both the highest affinities and the highest display levels. To evaluate our system, we chose three antibodies to improve their affinities and stabilities. We succeeded in simultaneously improving both affinities and stabilities of all three antibodies. Of note, we obtained an anti-TNFα antibody mutant with a Tm (dissolution temperature) value 12 °C higher and affinity 160-fold greater than the parent antibody after two rounds of cell proliferation and flow cytometric sorting. By using CHO cells with its advantages in protein folding, post-translational modifications, and code usage, this procedure is likely to be widely used in maturing antibodies and other proteins in the future.

摘要

抗体稳定性和亲和力是其在治疗和诊断应用中的两个重要特性。酵母展示和细菌展示等抗体展示技术已成功用于提高亲和力和稳定性。尽管哺乳动物细胞展示也已用于优化抗体亲和力,但尚未应用于提高抗体稳定性。此前,我们开发了一种中国仓鼠卵巢(CHO)细胞展示平台,其中使用激活诱导的胞苷脱氨酶(AID)诱导抗体突变,并使用该平台成功优化了抗体亲和力。在本研究中,我们开发了耐热(TR)CHO细胞,以同时优化抗体稳定性和亲和力。我们培养展示抗体突变文库的TR CHO细胞,并在41°C以上的温度下对其进行标记,富集展示具有最高亲和力和最高展示水平的抗体突变体的细胞。为了评估我们的系统,我们选择了三种抗体来提高它们的亲和力和稳定性。我们成功地同时提高了所有三种抗体的亲和力和稳定性。值得注意的是,经过两轮细胞增殖和流式细胞术分选后,我们获得了一种抗TNFα抗体突变体,其熔解温度(Tm)值比亲本抗体高12°C,亲和力比亲本抗体高160倍。通过利用CHO细胞在蛋白质折叠、翻译后修饰和密码子使用方面的优势,该方法未来可能会广泛应用于优化抗体和其他蛋白质。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e52/9404881/b4a1ebb05a3c/bioengineering-09-00360-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e52/9404881/5a83f0d8fed2/bioengineering-09-00360-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e52/9404881/0d717242759d/bioengineering-09-00360-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e52/9404881/6ef263cf396b/bioengineering-09-00360-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e52/9404881/f91cb102b102/bioengineering-09-00360-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e52/9404881/c6e85b401b47/bioengineering-09-00360-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e52/9404881/b667b8c55e3c/bioengineering-09-00360-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e52/9404881/b5ee28848b59/bioengineering-09-00360-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e52/9404881/5d3fe9cf2f69/bioengineering-09-00360-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e52/9404881/f2e327518bac/bioengineering-09-00360-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e52/9404881/b0fba86b71e4/bioengineering-09-00360-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e52/9404881/6621b93f2331/bioengineering-09-00360-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e52/9404881/e47e5e6c4279/bioengineering-09-00360-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e52/9404881/06154f25e8bf/bioengineering-09-00360-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e52/9404881/b4a1ebb05a3c/bioengineering-09-00360-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e52/9404881/5a83f0d8fed2/bioengineering-09-00360-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e52/9404881/0d717242759d/bioengineering-09-00360-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e52/9404881/6ef263cf396b/bioengineering-09-00360-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e52/9404881/f91cb102b102/bioengineering-09-00360-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e52/9404881/c6e85b401b47/bioengineering-09-00360-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e52/9404881/b667b8c55e3c/bioengineering-09-00360-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e52/9404881/b5ee28848b59/bioengineering-09-00360-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e52/9404881/5d3fe9cf2f69/bioengineering-09-00360-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e52/9404881/f2e327518bac/bioengineering-09-00360-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e52/9404881/b0fba86b71e4/bioengineering-09-00360-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e52/9404881/6621b93f2331/bioengineering-09-00360-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e52/9404881/e47e5e6c4279/bioengineering-09-00360-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e52/9404881/06154f25e8bf/bioengineering-09-00360-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e52/9404881/b4a1ebb05a3c/bioengineering-09-00360-g014.jpg

相似文献

1
Simultaneous Maturation of Single Chain Antibody Stability and Affinity by CHO Cell Display.通过CHO细胞展示实现单链抗体稳定性和亲和力的同时成熟
Bioengineering (Basel). 2022 Aug 2;9(8):360. doi: 10.3390/bioengineering9080360.
2
Coupling recombinase-mediated cassette exchange with somatic hypermutation for antibody affinity maturation in CHO cells.在CHO细胞中将重组酶介导的盒式交换与体细胞高频突变相结合以实现抗体亲和力成熟
Biotechnol Bioeng. 2016 Jan;113(1):39-51. doi: 10.1002/bit.25541. Epub 2015 Jul 31.
3
The application of adenine deaminase in antibody affinity maturation.腺嘌呤脱氨酶在抗体亲和力成熟中的应用。
Appl Microbiol Biotechnol. 2023 Apr;107(7-8):2661-2670. doi: 10.1007/s00253-022-12324-z. Epub 2023 Mar 16.
4
Activation-Induced Cytidine Deaminase Aided In Vitro Antibody Evolution.活化诱导胞苷脱氨酶辅助的体外抗体进化
Methods Mol Biol. 2018;1707:1-14. doi: 10.1007/978-1-4939-7474-0_1.
5
Identification of high affinity HER2 binding antibodies using CHO Fab surface display.利用 CHO Fab 表面展示技术鉴定高亲和力 HER2 结合抗体。
Protein Eng Des Sel. 2018 Mar 1;31(3):91-101. doi: 10.1093/protein/gzy004.
6
In vitro affinity maturation of a natural human antibody overcomes a barrier to in vivo affinity maturation.天然人源抗体的体外亲和力成熟克服了体内亲和力成熟的一个障碍。
MAbs. 2014 Mar-Apr;6(2):437-45. doi: 10.4161/mabs.27875. Epub 2014 Jan 16.
7
Antibody affinity maturation through combining display of two-chain paired antibody and precision flow cytometric sorting.通过展示双链配对抗体和精确流式细胞分选实现抗体亲和力成熟。
Appl Microbiol Biotechnol. 2016 Jul;100(13):5977-88. doi: 10.1007/s00253-016-7472-1. Epub 2016 May 3.
8
High efficiency CHO cell display-based antibody maturation.基于高效 CHO 细胞展示的抗体成熟。
Sci Rep. 2020 May 15;10(1):8102. doi: 10.1038/s41598-020-65044-7.
9
Mammalian cell display for the discovery and optimization of antibody therapeutics.哺乳动物细胞展示在抗体治疗药物的发现和优化中的应用。
Methods. 2014 Jan 1;65(1):44-56. doi: 10.1016/j.ymeth.2013.06.010. Epub 2013 Jun 20.
10
A mammalian cell display platform based on scFab transposition.基于单链抗体片段转座的哺乳动物细胞展示平台。
Antib Ther. 2023 May 26;6(3):157-169. doi: 10.1093/abt/tbad009. eCollection 2023 Jul.

引用本文的文献

1
Novel Data-Driven Mechanistic Modeling of Untargeted Metabolome Data Reveals Feed Component Effects in CHO Cell Bioprocess Using Column Generation-Based EFMs.基于柱生成的极端途径对非靶向代谢组数据进行新型数据驱动机制建模,揭示了CHO细胞生物过程中饲料成分的影响。
Biotechnol J. 2025 Jul;20(7):e70008. doi: 10.1002/biot.70008.
2
A Targeted Integration-Based CHO Cell Platform for Simultaneous Antibody Display and Secretion.一种基于靶向整合的CHO细胞平台,用于同时进行抗体展示和分泌。
Antibodies (Basel). 2025 Apr 28;14(2):38. doi: 10.3390/antib14020038.
3
A Strategy for Simultaneous Engineering of Interspecies Cross-Reactivity, Thermostability, and Expression of a Bispecific 5T4 x CD3 DART Molecule for Treatment of Solid Tumors.

本文引用的文献

1
Antibody-guided design and identification of CD25-binding small antibody mimetics using mammalian cell surface display.利用哺乳动物细胞表面展示技术进行抗体指导的设计和鉴定 CD25 结合的小分子抗体模拟物。
Sci Rep. 2021 Nov 11;11(1):22098. doi: 10.1038/s41598-021-01603-w.
2
Development of a novel mammalian display system for selection of antibodies against membrane proteins.开发一种新型的哺乳动物展示系统,用于选择针对膜蛋白的抗体。
J Biol Chem. 2020 Dec 25;295(52):18436-18448. doi: 10.1074/jbc.RA120.015053. Epub 2020 Oct 30.
3
High efficiency CHO cell display-based antibody maturation.
一种同时改造双特异性5T4 x CD3 DART分子的种间交叉反应性、热稳定性和表达以治疗实体瘤的策略。
Antibodies (Basel). 2025 Jan 17;14(1):7. doi: 10.3390/antib14010007.
4
Development of a new affinity maturation protocol for the construction of an internalizing anti-nucleolin antibody library.开发一种新的亲和力成熟方案,用于构建可内化抗核仁素抗体文库。
Sci Rep. 2024 May 8;14(1):10608. doi: 10.1038/s41598-024-61230-z.
5
Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties.拓展具有类药性理化性质的抗体的发现和筛选的常规工具包的方法。
MAbs. 2023 Jan-Dec;15(1):2164459. doi: 10.1080/19420862.2022.2164459.
基于高效 CHO 细胞展示的抗体成熟。
Sci Rep. 2020 May 15;10(1):8102. doi: 10.1038/s41598-020-65044-7.
4
In vitro affinity maturation of antibody against membrane-bound GPCR molecules.针对膜结合 GPCR 分子的抗体的体外亲和力成熟。
Appl Microbiol Biotechnol. 2019 Sep;103(18):7703-7717. doi: 10.1007/s00253-019-10030-x. Epub 2019 Jul 29.
5
Parallel Evolution of Antibody Affinity and Thermal Stability for Optimal Biotherapeutic Development.抗体亲和力与热稳定性的平行进化以实现最佳生物治疗药物开发
Methods Mol Biol. 2018;1827:457-477. doi: 10.1007/978-1-4939-8648-4_23.
6
Anti-CTLA-4 therapy requires an Fc domain for efficacy.抗 CTLA-4 治疗需要 Fc 结构域才能发挥疗效。
Proc Natl Acad Sci U S A. 2018 Apr 10;115(15):3912-3917. doi: 10.1073/pnas.1801524115. Epub 2018 Mar 26.
7
ABodyBuilder: Automated antibody structure prediction with data-driven accuracy estimation.ABodyBuilder:基于数据驱动的准确性估计进行自动化抗体结构预测。
MAbs. 2016 Oct;8(7):1259-1268. doi: 10.1080/19420862.2016.1205773. Epub 2016 Jul 8.
8
Optimizing antibody expression by using the naturally occurring framework diversity in a live bacterial antibody display system.利用活细菌抗体展示系统中天然存在的框架多样性优化抗体表达。
Sci Rep. 2015 Dec 3;5:17488. doi: 10.1038/srep17488.
9
Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging.工程化高亲和力PD-1变体用于优化免疫治疗和免疫PET成像。
Proc Natl Acad Sci U S A. 2015 Nov 24;112(47):E6506-14. doi: 10.1073/pnas.1519623112. Epub 2015 Nov 10.
10
Coupling recombinase-mediated cassette exchange with somatic hypermutation for antibody affinity maturation in CHO cells.在CHO细胞中将重组酶介导的盒式交换与体细胞高频突变相结合以实现抗体亲和力成熟
Biotechnol Bioeng. 2016 Jan;113(1):39-51. doi: 10.1002/bit.25541. Epub 2015 Jul 31.